Furthermore, HDAC inhibitors have been reported to disrupt the tumor microenvironment by suppressing the activity and aggregation of myeloid-derived suppressor cells (MDSCs), thereby enhancing tumor-specific immune responses 38. Here, HDAC9 is linked to neoplasm.